These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16005383)

  • 61. Genetic and clinical correlates of season of birth of schizophrenics.
    Kitamura T; Takazawa N; Moridaira J; Machizawa S; Nakagawa Y
    Psychiatry Clin Neurosci; 1995 Aug; 49(4):189-93. PubMed ID: 9179936
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects.
    Wei J; Ramchand CN; Hemmings GP
    Schizophr Res; 1992 Dec; 8(2):103-10. PubMed ID: 1360811
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Positive and negative symptoms. Relation to familial transmission of schizophrenia.
    Baron M; Gruen RS; Romo-Gruen JM
    Br J Psychiatry; 1992 Nov; 161():610-4. PubMed ID: 1422608
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Communication disturbances in schizophrenia: a two-process formulation.
    Docherty NM
    Compr Psychiatry; 1995; 36(3):182-6. PubMed ID: 7648840
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Response to neuroleptic drugs as a device for classifying schizophrenia.
    Brown WA; Herz LR
    Schizophr Bull; 1989; 15(1):123-9. PubMed ID: 2566199
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differences in [3H]-spiperone binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic patients.
    Grodzicki J; Pardo M; Schved G; Schlosberg A; Fuchs S; Kanety H
    Biol Psychiatry; 1990 Jun; 27(12):1327-30. PubMed ID: 1973057
    [No Abstract]   [Full Text] [Related]  

  • 67. Striatal dysfunction in patients with schizophrenia and their unaffected first-degree relatives.
    Li Z; Yan C; Lv QY; Yi ZH; Zhang JY; Wang JH; Lui SSY; Xu YF; Cheung EFC; Gur RE; Gur RC; Chan RCK
    Schizophr Res; 2018 May; 195():215-221. PubMed ID: 28867519
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.
    Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
    Schizophr Res; 2002 Jan; 53(1-2):145-59. PubMed ID: 11728846
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quality of life in schizophrenia in India: comparison of three approaches.
    Lobana A; Mattoo SK; Basu D; Gupta N
    Acta Psychiatr Scand; 2001 Jul; 104(1):51-5. PubMed ID: 11437750
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 3H-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment.
    Laufer N; Spivak B; Holdengreber V; Zipser J; Kosower N; Ragolsky M; Weizman A
    Clin Neuropharmacol; 1999; 22(2):110-4. PubMed ID: 10202608
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Negative and deficit symptoms in schizophrenia do respond to neuroleptics.
    Goldberg SC
    Schizophr Bull; 1985; 11(3):453-6. PubMed ID: 2863872
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication.
    Heilä H; Isometsä ET; Henriksson MM; Heikkinen ME; Marttunen MJ; Lönnqvist JK
    J Clin Psychiatry; 1999 Mar; 60(3):200-8. PubMed ID: 10192600
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Corneal temperature in schizophrenia patients.
    Shiloh R; Munitz H; Portuguese S; Gross-Isseroff R; Sigler M; Bodinger L; Katz N; Stryjer R; Hermesh H; Weizman A
    Int J Neuropsychopharmacol; 2005 Dec; 8(4):537-47. PubMed ID: 15927092
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Maudsley Family Study. I: Structural brain changes on magnetic resonance imaging in familial schizophrenia.
    Sharma T; du Boulay G; Lewis S; Sigmundsson T; Gurling H; Murray R
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Nov; 21(8):1297-315. PubMed ID: 9460093
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The relationship of symptomatology and medication to electrodermal activity in schizophrenia.
    Green MF; Nuechterlein KH; Satz P
    Psychophysiology; 1989 Mar; 26(2):148-57. PubMed ID: 2567035
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study.
    Galdi J; Rieder RO; Silber D; Bonato RR
    Psychol Med; 1981 Nov; 11(4):713-28. PubMed ID: 6119718
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Life events, relatives' expressed emotion and maintenance neuroleptics in schizophrenic relapse.
    Leff J; Kuipers L; Berkowitz R; Vaughn C; Sturgeon D
    Psychol Med; 1983 Nov; 13(4):799-806. PubMed ID: 6141582
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Familial risks and reproductive fitness in schizophrenia.
    Battaglia M; Bellodi L
    Schizophr Bull; 1996; 22(2):191-5. PubMed ID: 8782280
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The risk-benefit ratio of the proposed DSM-5 attenuated psychosis syndrome.
    Woods SW; McGlashan TH
    Am J Psychiatry; 2011 Dec; 168(12):1338; author reply 1338. PubMed ID: 22193675
    [No Abstract]   [Full Text] [Related]  

  • 80. Clinical heterogeneity in schizophrenia and the pattern of psychopathology in relatives: results from an epidemiologically based family study.
    Kendler KS; McGuire M; Gruenberg AM; Walsh D
    Acta Psychiatr Scand; 1994 May; 89(5):294-300. PubMed ID: 8067266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.